SYNSORB Pk

Drug Profile

SYNSORB Pk

Alternative Names: SYNSORB Pk; TAK 751S

Latest Information Update: 30 Jul 2003

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator SYNSORB Biotech
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Escherichia coli infections

Most Recent Events

  • 19 Jan 2001 Phase-III clinical trials for Escherichia coli infections in USA (PO)
  • 10 Jan 2001 SYNSORB Biotech has suspended further development of SYNSORB Pk® but the US NIH will continue their phase III trial on SYNSORB Pk® investigating a different clinical endpoint
  • 10 Jan 2001 Suspended-III for Escherichia coli infections in Argentina (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top